| Name | ASN-002 |
|---|---|
| Synonyms |
GUSACITINIB (ASN-002)
1-[5,6-Dihydro-4-[[4-(4-hydroxy-1-piperidinyl)phenyl]amino]-5-oxopyrimido[4,5-d]pyridazin-2-yl]-4-piperidineacetonitrile GUSACITINIB 2-(1-(4-((4-(4-hydroxypiperidin-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile Syk,Janus kinase,Gusacitinib,Spleen tyrosine kinase,JAK,ASN 002,ASN002,Inhibitor,inhibit 4-Piperidineacetonitrile, 1-[5,6-dihydro-4-[[4-(4-hydroxy-1-piperidinyl)phenyl]amino]-5-oxopyrimido[4,5-d]pyridazin-2-yl] Gusacitinib, 10 mM in DMSO ASN-002 (Gusacitinib |
| Description | ASN-002 is a potent dual inhibitor of spleen tyrosine kinase (SYK) and janus kinase (JAK) with IC50 values of 5-46 nM. |
|---|---|
| Related Catalog | |
| Target |
IC50: 5-46 nM (SYK, JAK)[1]. |
| In Vitro | In mechanistic cell-based studies involving IgE and cytokine stimulations, ASN-002 strongly suppresses the SYK and JAK family kinase signaling pathways measured as pLAT and pSTAT levels, respectively. ASN-002 shows anti-proliferative activity in a broad panel of human cancer cell lines including DHL6, DHL4, OCI-LY10, H929, Pfeiffer, HT-1376, and Lovo, suggesting activity in both solid and hematological tumor types[1]. |
| In Vivo | In a multiple myeloma (H929) xenograft model, ASN-002 exhibits significant efficacy in inhibiting tumor growth (>95%). It also significantly delays the onset of hind limb paralysis in the human erythroleukemia (HEL) mouse model. ASN-002 has good oral bioavailability, metabolic stability, is not a Pgp substrate, and shows little to no inhibition of CYP450 isozymes. ASN-002 shows a favorable safety profile in rat and dog toxicology studies[1]. |
| References |
| Molecular Formula | C24H28N8O2 |
|---|---|
| Molecular Weight | 460.53 |